Quantum BioPharma rated BUY with $8 target
Quantum BioPharma Ltd. (QNTM) reports that investment bank Rodman & Renshaw has initiated analyst coverage on the company with a BUY rating and a US$8 price target.
Rhea-AI Filing Summary
Quantum BioPharma Ltd. (QNTM) reports that investment bank Rodman & Renshaw has initiated analyst coverage on the company with a BUY rating and a US$8 price target. The company states this coverage is unpaid and that it provided no consideration or fees for the report.
Quantum describes itself as a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse, led by its preclinical multiple-sclerosis candidate Lucid-MS. Through its subsidiary and spin-out structure, Quantum also retains an equity interest and royalty rights in the consumer product UNBUZZD™.
Positive
- None.
Negative
- None.
Filing Explained
As of June 30, 2026, Quantum reported a 19.48% Unbuzzd stake and royalties that step down after total payments reach $250 million.
The filing adds that Quantum BioPharma reported retaining a
The agreement also provides Quantum royalties equal to
Key Figures
Analyst price target: US$8 per share
Ownership in Unbuzzd Wellness Inc.: 19.48%
Royalty rate on unbuzzd™ sales (initial): 7% of sales
+3 more
6 metrics
Analyst price target
US$8 per share
Rodman & Renshaw initiation report on Quantum BioPharma
Ownership in Unbuzzd Wellness Inc.
19.48%
Equity stake as of June 30, 2026
Royalty rate on unbuzzd™ sales (initial)
7% of sales
Applies until Quantum BioPharma has received $250 million in royalty payments
Royalty payment threshold
$250 million
Cumulative royalties from unbuzzd™ sales before rate decreases
Royalty rate on unbuzzd™ sales (after threshold)
3% of sales
Applies in perpetuity after $250 million in total royalties is reached
Analyst coverage initiation date
September 17, 2026
Date of press release and Rodman & Renshaw initiation
Key Terms
BUY rating, price target, royalty payments, new chemical entity, +1 more
5 terms
BUY rating financial
"initiated coverage of Quantum BioPharma with a BUY rating and a US$8 price"
A buy rating is an analyst’s recommendation that a stock is expected to rise in value and is a good purchase relative to other investment choices. It matters to investors because such ratings can influence buying demand and share prices and act like a trusted product review: they summarize research and risk expectations so investors can decide whether to add a stock to their portfolio, while still weighing other information.
price target financial
"initiated coverage of Quantum BioPharma with a BUY rating and a US$8 price target"
A price target is an analyst’s estimate of the future value of a stock, typically expressed as a single number for a set time frame. It matters to investors because it acts like an expected selling price when appraising a house—helping people decide whether a stock looks cheap, fairly priced, or expensive compared with current market price and guiding buy, hold or sell decisions; it is an opinion, not a guarantee.
royalty payments financial
"The agreement with Unbuzzd also includes royalty payments of 7% of sales"
Payments made to the owner of an asset, patent, trademark, mineral right, or creative work in exchange for permission to use it; they are typically a percentage of sales or a fixed fee per unit sold. For investors, royalty payments represent a steady income stream tied to the underlying product’s sales performance, similar to collecting rent from tenants — predictable cash flow that can reduce risk or add value when evaluating a company’s revenue sources.
new chemical entity medical
"Lucid-MS is a patented new chemical entity shown to prevent and reverse"
A new chemical entity (NCE) is a drug whose active ingredient has never been previously approved or marketed; it’s a wholly new molecule rather than a new use of an existing compound. For investors, NCEs matter because they offer fresh commercial opportunities, potential patent and regulatory exclusivity, and correspondingly higher upside if successful — but they also carry greater development and regulatory risk, like betting on an untested recipe.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of applicable"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Quantum BioPharma (QNTM) announce in this Form 6-K?
Quantum BioPharma announced that Rodman & Renshaw initiated analyst coverage on the company with a BUY rating and a US$8 price target. The company also reiterates its focus on neurodegenerative and metabolic disorders and alcohol misuse, including its lead candidate Lucid-MS.
What rating and price target did Rodman & Renshaw assign to QNTM?
Rodman & Renshaw initiated coverage on Quantum BioPharma with a BUY rating and a US$8 price target. The initiation report was authored by Michael G. King Jr., Director of Research and Senior Biotechnology Analyst at Rodman & Renshaw.
Did Quantum BioPharma pay Rodman & Renshaw for this analyst coverage?
No. Quantum BioPharma states the coverage is unpaid and that it provided no consideration and paid no fees to Rodman & Renshaw for the initiation research report on the company.
What is Quantum BioPharma’s business focus according to the 6-K?
Quantum BioPharma describes itself as a biopharmaceutical company building a portfolio of innovative assets for neurodegenerative disorders, metabolic disorders, and alcohol misuse disorders, with multiple drug candidates in different stages of development, led by its patented compound Lucid-MS for multiple sclerosis in preclinical models.
What ownership stake does QNTM hold in Unbuzzd Wellness Inc. and what royalties apply?
Quantum BioPharma reports owning 19.48% of Unbuzzd Wellness Inc. as of June 30, 2026. It is entitled to 7% royalty payments on unbuzzd™ sales until it receives $250 million, after which the royalty decreases to 3% in perpetuity.
What is Lucid-MS as described by Quantum BioPharma?
Lucid-MS is described as a patented new chemical entity that has been shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. It is the lead compound being developed through Quantum’s wholly owned subsidiary, Lucid Psycheceuticals Inc.
AI-generated analysis. How Rhea-AI works. Not financial advice.
